Measles at a glance: DPR Korea, 2018

Through the sheer will of its political leadership DPR Korea has maintained high immunization coverage, established an effective surveillance system and instituted collective responsibility of health workers and community. As a result, the country has surged forward to be at the forefront of the fight against measles. Measles at a Glance DPR Korea, 2018 Measles surveillance What made DPR Korea successful in combating measles?  Strong leadership  Careful planning and implementati on  Strong health system  A passionate workforce that took ownership of the programme  Community parti cipati on  Quality assurance  Careful monitoring Serum sample with serology result within 4 days of sample receipt in the laboratory reporti ng sites for measles and rubella senti nel sites for congenital rubella syndrome (CRS) surveillance accredited measles and rubella laboratory Serum samples received in laboratory within 5 days of sample collecti on Suspected cases with serological testi ng Suspected cases with fever and rash Provinces meeti ng discarded non-measles, non-rubella rate of 2 or more per 100 000 populati on Suspected cases with serum samples collected Discarded non measles non- rubella rate per 100,000 populati on 7954 222 1 Household doctors located at the Ri clinics visit the community every day AcƟ ve case search AnƟ -epidemic doctors conduct detailed invesƟ gaƟ on of detected cases Surveillance performance indicators (2015–2017) Coverage of 1st and 2nd doses of measles vaccine and no. of measles cases (2002-2016) Measles cases Routi ne coverage MCV-1 Significant events 106 total suspected cases 106 discarded cases (non-measles,non- rubella) 0 cases classifi ed as measles 0 cases classifi ed as rubella 0 clinically measles or rubella compati ble Findings of suspected measles cases in 2017 DPR Korea too k cognizance o f the threat m easles posed to its ci ti zens, introdu cing the meas les- containing vac cine (MCV) int o its health sy stem in 1968. With th e launch of th e EPI in the ea rly 1980s and combined eff orts of all le aders, health workers and communi ty members to contain the v irus, no sporadic incid ent or outbrea k has been rep orted since 2014. Co ordinati on with internati onal establishment s has also help ed the countr y to strive towards achieving a h igh level of po pulati on immunity aga inst the dread ed disease. 25 030 070 Total populati on 17.68/1 000 Under-fi ve mortality 1 696 094 Under-fi ve populati on 3 Directly governed citi es 12 Provinces DPR Korea: An overview 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Routi ne coverage MCV-2 SIA coverage 100 80 60 40 20 0 Year 3550 Co ve ra ge Introducti on of disease surveillance for measles and rubella 2006 Nati onwide MCV SIA for individuals aged 6 months– 45 years subsequent to successfully managing a huge measles outbreak 2007 Introducti on of MCV2; fi rst accreditati on of the Nati onal Laboratory for MR by WHO 2008 Country’s surveillance system ably detects three imported cases of measles from neighbouring country 2014 MR SIA for children aged 12 months–16 years in selected areas 2015-2016 Verifi cati on that DPR Korea has eliminated measles 2018 Introducti on of MCV1 with domesti c vaccine 1967 1997 Switch to WHO prequalifi ed MCV MCV: Measles-containing vaccine SIA: Supplementary immunizati on acti vity MR: Measles–rubella Through the sheer will of its political leadership DPR Korea has maintained high immunization coverage, established an effective surveillance system and instituted collective responsibility of health workers and community. As a result, the country has surged forward to be at the forefront of the fight against measles. Measles at a Glance DPR Korea, 2018 Measles surveillance What made DPR Korea successful in combating measles?  Strong leadership  Careful planning and implementati on  Strong health system  A passionate workforce that took ownership of the programme  Community parti cipati on  Quality assurance  Careful monitoring Serum sample with serology result within 4 days of sample receipt in the laboratory reporti ng sites for measles and rubella senti nel sites for congenital rubella syndrome (CRS) surveillance accredited measles and rubella laboratory Serum samples received in laboratory within 5 days of sample collecti on Suspected cases with serological testi ng Suspected cases with fever and rash Provinces meeti ng discarded non-measles, non-rubella rate of 2 or more per 100 000 populati on Suspected cases with serum samples collected Discarded non measles non- rubella rate per 100,000 populati on 7954 222 1 Household doctors located at the Ri clinics visit the community every day AcƟ ve case search AnƟ -epidemic doctors conduct detailed invesƟ gaƟ on of detected cases Surveillance performance indicators (2015–2017)